Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Name: Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study
Creator: April Armstrong
Published: 2026-08-10T15:29:45.364Z
Keywords: Immunology, Dermatology, Psoriasis, IL-17A Signaling Pathway

Armstrong, April; Merola, Joseph; Chughtai, Rukhsar; Fotiou, Konstantinos; Ngantcha, Marcus; Sabatino, Silvia; Megna, Matteo; Man, Xiao-Yong; Honma, Masaru; Carrascosa, Jose-Manuel; Pinter, Andreas

doi:10.17632/cgrc5mt72w.1

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Published: 10 August 2026| Version 1 | DOI: 10.17632/cgrc5mt72w.1

Contributors:

April Armstrong, Joseph Merola, Rukhsar Chughtai, Konstantinos Fotiou, Marcus Ngantcha, Silvia Sabatino, Matteo Megna, Xiao-Yong Man, Masaru Honma, Jose-Manuel Carrascosa, Andreas Pinter

Description

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Files

Funders

Eli Lilly (United States)
Indiana, Indianapolis

Early and Maintained Treat-to-Target Response with Ixekizumab up to 5 Years in Moderate-to-Severe Psoriasis: Analysis of the UNCOVER-3 Study

Description

Files

Categories

Funders

Licence